Navigation Links
Revised GAAP earnings guidance for AbbVie Inc for the Financial Year ending December 31, 2014 and Third Quarter ending September 30, 2014; Confirms Adjusted Earnings Guidance
Date:9/3/2014

e in 2014.

In addition, excluding the potential impact of the transaction with Shire, AbbVie is confirming its adjusted earnings-per-share guidance for the full-year 2014 of $3.06 to $3.16.

AbbVie's 2014 outlook continues to exclude any potential revenue from the expected 2014 U.S. launch of its hepatitis C (HCV) therapy.

Revised Third-Quarter 2014 GAAP guidance:

Excluding the potential impact of the transaction with Shire, AbbVie is also reducing its Q3 2014 earnings-per-share guidance range on a GAAP basis to $0.41 to $0.43 after reflecting the reduction of $0.27 per share in relation to the initial commitment of the upfront investments in Q3 as stated above.

In addition, excluding the potential impact of the transaction with Shire, AbbVie is confirming its adjusted earnings-per-share guidance for the third quarter 2014 of $0.77 to $0.79, which also continues to exclude any potential revenue from the expected 2014 U.S. launch of its hepatitis C (HCV) therapy.

The Revised Full-Year 2014 GAAP guidance and Revised Third-Quarter 2014 GAAP guidance constitute profit forecasts for the purposes of the Code (the "AbbVie Profit Forecasts").

In the above statements, diluted earnings per share is defined as net earnings attributable to AbbVie divided by the weighted average number of diluted shares for the year. The computation of weighted average shares for diluted earnings per share adds back incremental shares from assumed conversions of stock options, net of assumed share repurchases and LTIP shares to the weighted average shares of basic earnings per shares. 

2.            Basis of preparation

The AbbVie Profit Forecasts have been prepared on a basis consistent with the accounting policies for AbbVie which are in accordance with generally accepted accounting standards in the U.S. and those which AbbVie anti
'/>"/>

SOURCE AbbVie
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. International Probiotics Association Excited To Learn The FDA Has Decided To Issue A New, Revised NDI Draft Guidance
2. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
3. Preliminary Figures for 2011: Sartorius Grows at Double-Digit Rates and Boosts Operating Earnings by More Than 30%
4. Bacterin International Holdings, Inc. Schedules Fourth Quarter 2011 Financial Earnings Conference Call
5. WuXi PharmaTech Schedules Second-Quarter 2012 Earnings Release
6. Life Technologies Sets 2nd Quarter 2012 Earnings Release Date for Tuesday, July 31, 2012
7. Haemonetics Reports First Quarter Fiscal 2013 Results, Completes Acquisition of Palls Transfusion Medicine Business, Affirms Fiscal 2013 Earnings Guidance, Provides Preliminary Outlook for Fiscal 2014 and Announces Share Repurchase
8. Perrigo Reports Record Fourth Quarter and Fiscal Year Revenue, Earnings and Cash Flow From Operations
9. Cambrex Reschedules Third Quarter 2012 Financial Results and Earnings Call Date to November 5, 2012
10. Sigma-Aldrich Announces Q4 2012 Earnings Conference Call
11. Zynga, Inc. Fourth-Quarter Earnings and Sales Topped Wall Street Estimates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Dr. Greg Leyer of ... annual Scripps Natural Supplements Pre-Conference seminar on probiotics in San ... an annual continuing education conference for health care professionals. This ... the topic of probiotics in health. Dr. Leyer spoke about ...
(Date:1/22/2015)... DIEGO , Jan. 22, 2015   Cypher ... and Sequenom, Inc. (NASDAQ: SQNM ), ... development agreement for next generation noninvasive prenatal tests ... genome interpretation technology, called Mantis™, to advance analysis ...
(Date:12/24/2014)... 24, 2014  United Therapeutics Corporation (NASDAQ: UTHR ... MDT ) has submitted a pre-market approval application to ... use of Medtronic,s SynchroMed ® II implantable drug ... with United Therapeutics, Remodulin ® (treprostinil) Injection delivered ...
(Date:12/24/2014)... Louis, Missouri (PRWEB) December 23, 2014 GMO ... biotechnology company, Syngenta, are in the process of being consolidated ... case is In Re: Syngenta AG MIR 162 Corn Litigation, ... District of Kansas. , Management of the Syngenta GMO corn ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... Odenheim, director of IT services at Synteract, Inc., ... on Selecting the Optimum EDC Platform to Support your ... East Coast conference , to be held in Philadelphia, March ... March 28, discussing a variety of drivers to consider when ...
... capacitors (ECs), also known as supercapacitors or ultracapacitors, differ ... TV or computer in that they store substantially higher ... storage devices as they charge and discharge faster than ... densities, only a fraction of the energy density of ...
... 2012 Sigma-Aldrich® Corporation (NASDAQ: SIAL ) ... Wuxi, China, that will provide localized packaging, analytical services ... Company,s research and industrial customers in the region. ... in industrial growth, and now we are viewing a ...
Cached Biology Technology:Synteract Director of IT Services Toby Odenheim Speaking at March 2012 Outsourcing in Clinical Trials East Coast Conference 2Synteract Director of IT Services Toby Odenheim Speaking at March 2012 Outsourcing in Clinical Trials East Coast Conference 3Researchers develop graphene supercapacitor holding promise for portable electronics 2Researchers develop graphene supercapacitor holding promise for portable electronics 3Researchers develop graphene supercapacitor holding promise for portable electronics 4Sigma-Aldrich Opens New Wuxi Packaging and Quality Control Facilities to Enhance Capabilities Serving China and Asia-Pacific Region 2Sigma-Aldrich Opens New Wuxi Packaging and Quality Control Facilities to Enhance Capabilities Serving China and Asia-Pacific Region 3
(Date:12/11/2014)... WINSTON SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ...
(Date:12/10/2014)... 8, 2014 You,ve been here before: you desperately need to ... site key or the answer to your secret question. What,s your ... Today, Hoyos Labs , a digital infrastructure security company, launches ... the frustration that comes with usernames, passwords and PINs – ...
(Date:12/10/2014)... 2014  Wake Forest Baptist Medical Center today announced plans for ... Funding for this $50 million capital project is part of ... summer. The medical education building will be ... complex, adjacent to 525@vine in Wake Forest Innovation Quarter. Construction ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... 2008 Changing the sugars attached to a hormone produced ... 50 percent, a research group at Washington University School of ... alter a reproductive "thermostat," unveiling part of an intricate regulatory ... fertility. "To adjust for the right amount of key ...
... PHILADELPHIA, May 16, 2008 New data show that ... painful oral mucositis (OM) and improves quality of life ... These data will be reported in two separate presentations, ... tomorrow as a poster session, at the 33rd Annual ...
... of Forest Research presents the preliminary findings of ... landscape-scale experiments on how forest management affects western ... Research team includes U.S. Forest Service, Humboldt State ... Georgia and Wildlife Conservation Society scientists collaborating in ...
Cached Biology News:Disabling mouse enzyme increases fertility 2CAPHOSOL relieves oral mucositis and improves quality-of-life in cancer patients 2CAPHOSOL relieves oral mucositis and improves quality-of-life in cancer patients 3CAPHOSOL relieves oral mucositis and improves quality-of-life in cancer patients 4Pioneering landscape-scale research releases first findings 2
... and pathophysiological stressful conditions trigger the synthesis ... heat shock proteins (HSPs), more appropriately called ... Hsp90 family of proteins in mammalian cells ... and Trap-1 (Hsp75). It was found that ...
Custom LNA Oligonucleotide synthesis ,High quality Custom LNA Oligonucleotides are available for a variety of different specialty applications and innovative products. ,Please inquire for further...
... SOS Protein Solubility Service, We ... , New SOS technology yields the best ... parameters applied on each clone submitted , ... ,The new protein Solubility Optimization Service ...
... proteomic scale kinase profiling, quantitative measurement ... discovery research built on the flexible ... platform. These microarrays are available as ... Substrate - Peptide Microarray Service. ...
Biology Products: